Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
Key Highlights
- ➤Niki’s DiamiR to perform plasma-based APOE genotyping for GAP’s Bio-Hermes-002 cohort
- ➤Bio-Hermes-002 compares blood and digital biomarkers with amyloid PET and cognitive assessments
- ➤APOE ε4 is the strongest known genetic risk factor for late-onset Alzheimer’s disease
- ➤Genotyping banked plasma adds genetic data without requiring additional blood draws
- ➤GAP’s cohort emphasizes recruitment from underrepresented communities
Expert Statements
Alidad Mireskandari, President and Chief Operating Officer of Niki BioSolutions
“We are proud to contribute DiamiR’s plasma-based APOE genotyping to the Bio-Hermes cohort. Determining APOE status from plasma unlocks the value of samples already collected, helping researchers better interpret blood-based biomarkers and design more efficient trials. This collaboration also expands our visibility with the biopharma and diagnostics companies that rely on Bio-Hermes data.”
John Dwyer, President & CEO of the Global Alzheimer’s Platform Foundation
“Bio-Hermes was designed to give the field data that will enhance the design and execution of Alzheimer's clinical trials. We are pleased to collaborate with DiamiR. Adding APOE genotype makes Bio-Hermes an even more valuable resource.”
Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer’s biomarker cohort
PRINCETON, N.J., and NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. (“DiamiR”), will perform apolipoprotein E (APOE) genotyping on plasma samples from the Global Alzheimer’s Platform Foundation® (“GAP”) Bio-Hermes-002 study cohort.
Get started
Create a free account to read the full story.